
    
      Study Type: Interventional Study Design: A randomized, two-way crossover, open-label,
      single-dose, fasting design.

      Official Title: A TWO-WAY CROSSOVER, OPEN-LABEL, SINGLE-DOSE, FED, BIOEQUIVALENCE STUDY OF
      GRISEOFULVIN 125 mg/5 mL SUSPENSION VERSUS GRIFULVIN VÂ® 125 mg/5 mL SUSPENSION IN NORMAL,
      HEALTHY, NON-SMOKING MALE AND FEMALE SUBJECTS

      Further study details as provided by Actavis Elizabeth LLC:

      Primary Outcome Measures:

      Rate and Extend of Absorption
    
  